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The endocannabinoids 2-arachidonoyl glycerol (2-
AG) and N-arachidonoyl ethanolamine (anandamide)
are principally degraded by monoacylglycerol lipase
(MAGL) and fatty acid amide hydrolase (FAAH),
respectively. The recent discovery of O-aryl carba-
mates such as JZL184 as selective MAGL inhibitors
has enabled functional investigation of 2-AG sig-
naling pathways in vivo. Nonetheless, JZL184 and
other reported MAGL inhibitors still display low-level
cross-reactivity with FAAH and peripheral carboxy-
lesterases, which can complicate their use in certain
biological studies. Here, we report a distinct class
of O-hexafluoroisopropyl (HFIP) carbamates that
inhibits MAGL in vitro and in vivo with excellent
potency and greatly improved selectivity, including
showing no detectable cross-reactivity with FAAH.
These findings designate HFIP carbamates as a
versatile chemotype for inhibiting MAGL and should
encourage the pursuit of other serine hydrolase
inhibitors that bear reactive groups resembling the
structures of natural substrates.
INTRODUCTION
Endocannabinoids are lipid transmitters that serve as endoge-
nous ligands for the cannabinoid receptors CB1 and CB2, which
are also activated byD9-tetrahydrocannabinol, the psychoactive
ingredient of marijuana. The two major endocannabinoids, 2-
arachidonoyl glycerol (2-AG) and N-arachidonoyl ethanolamine
(anandamide or AEA), play important roles in a wide range of
physiological and pathological processes, including pain, cogni-
tion, emotionality, and feeding (Ligresti et al., 2009; Graham
et al., 2009; Di Marzo, 2008, 2009; De Petrocellis and Di Marzo,
2009; Fowler, 2008; Ahn et al., 2008; Guindon et al., 2011). The
signaling functions of 2-AG and AEA are terminated by enzy-
matic hydrolysis in processes principally mediated by the serine
hydrolasesmonoacylglycerol lipase (MAGL) and fatty acid amideChemistry & Biology 19,hydrolase (FAAH), respectively (Ahn et al., 2008). Additional
2-AG hydrolases exist, such as ABHD6 and ABHD12, and these
enzymes may also regulate specific endocannabinoid pathways
in vivo (Blankman et al., 2007; Marrs et al., 2010).
Pharmacologic and/or genetic disruption of MAGL and FAAH
has provided evidence that elevations in endocannabinoid
signaling can produce an intriguing subset of the behavioral
effects of direct CB1 agonists. FAAH(/) mice or rodents treated
with FAAH inhibitors, for instance, show antihyperalgesia
and antianxiety/depression without exhibiting psychotropic
responses or deficits in motor function (Cravatt et al., 2001;
Lichtman et al., 2004; Kathuria et al., 2003; Ahn et al., 2009).
MAGL inhibitors show a similar, but somewhat broader spec-
trum of CB1-dependent behavioral effects (Long et al., 2009a),
and, at high doses, can lead to desensitization and downregula-
tion of CB1 receptors (Schlosburg et al., 2010). Dual FAAH/
MAGL inhibitors, on the other hand, promote cataleptic and
drug-dependence behaviors in mice that are more reminiscent
of direct CB1 agonists (Long et al., 2009c). These data designate
selective FAAH and MAGL inhibitors as useful probes for dis-
secting the functions of different branches of the endocannabi-
noid system and as potential therapeutic agents for treating
pain and neuropsychiatric disorders. However, the results also
underscore the importance of maintaining high levels of selec-
tivity to avoid simultaneous blockade of both FAAH and MAGL.
Lead MAGL inhibitors from the O-aryl carbamate class, such
as JZL184, which inactivate MAGL by covalent carbamylation
of the enzyme’s serine nucleophile, show good selectivity
(>100-fold) for MAGL over FAAH, ABHD6, and most other serine
hydrolases (Long et al., 2009a, 2010). However, we have found
that the residual, low-level cross-reactivity displayed by
JZL184 for FAAH does lead to partial inhibition of this enzyme
following high-dosing and chronic treatment regimens (Long
et al., 2009a, 2009b; Schlosburg et al., 2010). Thus, a need
remains to identify inhibitors that showmore complete selectivity
for MAGL over FAAH to avoid the potentially confounding effects
of dual activation of 2-AG and AEA pathways in vivo. Here, we
report the discovery and characterization of structurally distinct
carbamate inhibitors bearing a hexafluoroisopropanol-leaving
group that act as highly selective and in vivo-active inhibitors
of MAGL. Competitive activity-based protein profiling (ABPP)
and endocannabinoid-specific biomarker assays confirmed579–588, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 579
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JZL184, here named KML29, potently and selectively inhibited
MAGL in vitro and in vivo with minimal cross-reactivity toward
other central and peripheral serine hydrolases, including no
detectable activity against FAAH.
RESULTS
Discovery of HFIP Carbamates as Selective MAGL
Inhibitors
In our search for new classes of inhibitors that might display
improved selectivity for MAGL over FAAH, we sought to replace
the p-nitrophenol leaving group of JZL184 with another electro-
philic moiety that better discriminated between these two
endocannabinoid hydrolases. We were particularly attracted to
hexafluoroisopropanol as a leaving group because it possesses
a low pKa value (9.3) and a structure that resembles the glyc-
erol of MAGL’s natural substrates (Figure 1A). It is furthermore
known that modification of the methylene proximal to the amide
on AEA impairs FAAH hydrolysis (Figure 1A) (Lang et al., 1999).
We therefore reasoned that HFIP carbamatesmight retain excel-
lent activity against MAGL while, at the same time, exhibiting
reduced inhibition of FAAH. We synthesized HFIP carbamate
analogs for three known endocannabinoid hydrolase inhibitors:
the MAGL-selective inhibitor JZL184 (KML29, Figure 1A) (Long
et al., 2009a, 2010); the ABHD6-selective inhibitor WWL70
(JW618, Figure 1A) (Li et al., 2007); and the dual MAGL/FAAH
inhibitor JZL195 (JW642, Figure 1A) (Long et al., 2009c, 2010).
We initially assayed each HFIP carbamate for inhibition
against MAGL, FAAH, ABHD6, and other mouse brain serine
hydrolases using competitive ABPP (Leung et al., 2003). In this
assay, cell or tissue proteomes are treated with inhibitors
followed by the serine hydrolase-directed activity-based probe
fluorophosphonate-rhodamine (FP-Rh), and inhibition is re-
corded as a reduction in FP-Rh probe labeling of individual
serine hydrolases following separation by SDS-PAGE and in-gel
fluorescence scanning. Competitive ABPP gels of mouse brain
membrane proteome revealed that HFIP carbamates exhibit
outstanding selectivity for MAGL over FAAH compared to the
corresponding O-aryl carbamates (Figure 1B; Table 1; and see
Figure S1 available online). The HFIP analog of JZL184,
KML29, for instance, showed complete selectivity for MAGL
over FAAH across the concentration range tested (0.001–
50 mM) and greater than 100-fold selectivity for ABHD6, the
only observable off target in the mouse brain proteome (Fig-
ure 1C; Table 1). This improvement in selectivity came without
any sacrifice in potency because KML29 and JZL184were found
to exhibit equivalent IC50 values for MAGL inhibition (Table 1).
Similar results were obtained using 2-AG and AEA substrate
assays, which confirmed that KML29 is a potent inhibitor of
2-AG hydrolysis, but did not affect AEA hydrolysis at any
concentration tested (Figure 1D). JW618, the HFIP analog of
the selective ABHD6 inhibitor WWL70 (Li et al., 2007), acted as
a dual MAGL/ABHD6 inhibitor with no detectable cross-reac-
tivity with FAAH (Figure 1B; Table 1). Finally, and perhaps most
surprisingly, JW642, the HFIP analog of the low nanomolar
dual MAGL/FAAH inhibitor JZL195, inhibited MAGL with
>1,000-fold greater potency than FAAH, indicating that simple
replacement of the p-nitrophenyl group with the HFIP group580 Chemistry & Biology 19, 579–588, May 25, 2012 ª2012 Elsevierwas sufficient to convert potent dual FAAH/MAGL inhibitors
into agents that displayed high selectivity for MAGL. That the
selectivities displayed by KML29 and JW642 for MAGL over
ABHD6 were nearly equivalent to those observed for their parent
p-nitrophenyl carbamates indicates that the HFIP group is
accommodated equally well by both of these enzymes, consis-
tent with their shared ability to hydrolyze the substrate analog
2-AG.
To gain further insight into the mode of inhibition of MAGL by
HFIP carbamates, we first determined by mass spectrometry
analysis that KML29 reacts with the catalytic serine nucleophile
of MAGL to form a stable, carbamylated adduct (Figures 2A and
2B). This covalent mechanism of inhibition mirrors that of the
p-nitrophenoxy carbamate JZL184 (Long et al., 2009b). We
also modeled the binding of KML29 to the MAGL active site
using recently described crystal structures of the human MAGL
(hMAGL) enzyme (Bertrand et al., 2010). The resulting model
provided evidence that the HFIP group of KML29 could bind to
MAGL in a similar manner to that predicted for the glycerol
moiety of 2-AG (Bertrand et al., 2010), including potential interac-
tions with the conserved active site residues His121 and Tyr194
(Figure 2C). Together, these data demonstrate that HFIP carba-
mates can serve as potent and selective inhibitors of MAGL
and possibly other 2-AG hydrolases.
KML29 Selectively Inhibits MAGL in Mice
Having demonstrated that KML29 is a potent and selective
MAGL inhibitor in vitro, we next evaluated the activity of this
compound in vivo. C57Bl/6 mice were treated with a dose range
(1–40 mg kg1, p.o.) of KML29 or JZL184, or vehicle, and after
4 hr were sacrificed, and their tissues removed and analyzed
by competitive ABPP to assess serine hydrolase activities (Fig-
ure 3A). KML29 and JZL184 showed comparable dose-depen-
dent blockade of MAGL activity in brain, with partial inhibition
observed at 5 mg kg1 and maximal inhibition achieved by
20 mg kg1. Consistent with the in vitro selectivity profile for
each inhibitor, JZL184 was found to partially inhibit FAAH at
the highest dose tested (40 mg kg1), whereas KML29 exhibited
complete selectivity over FAAH at all doses tested. Similar
profiles were generated for KML29 when administered to mice
intraperitoneally (i.p.) (Figure S2). We have previously noted
that the limited solubility of JZL184 necessitates sonication in
the chosen vehicle prior to administration. Prolonged sonication
and mild heating were also required for the dissolution of KML29
in vehicles for p.o. (PEG) or i.p. (saline:emulphor:ethanol [18:1:1])
routes of administration (see Experimental Procedures for
details).
Consistent with the dose-dependent inhibition of MAGL
observed by competitive ABPP, KML29 produced significant
elevations in brain 2-AG at doses as low as 5 mg kg1, and these
increases peaked at10-fold over vehicle controls at the 20 and
40 mg kg1 doses (Figure 3B). As previously reported for other
MAGL inhibitors (Long et al., 2009a, 2009b) and MAGL(/)
mice (Schlosburg et al., 2010), we observed, concomitant with
2-AG elevations, significant reductions in brain arachidonic
acid (AA). In contrast, brain levels for the endogenous FAAH
substrates AEA, N-palmitoylethanolamine (PEA), and N-oleoyle-
thanolamine (OEA) were unaltered by KML29 treatment at all
tested doses (Figure 3B). Finally, we measured residual MAGLLtd All rights reserved
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Figure 1. Discovery of HFIP Carbamates as Potent and Selective MAGL Inhibitors
(A) Structures of 2-AG, representativeO-aryl carbamate inhibitors of endocannabinoid hydrolases, and HFIP carbamate analogs of these inhibitors, showing the
bioisosteric nature of the HFIP group compared to the glycerol head group of MAGL substrate 2-AG.
(B) Competitive ABPP gels comparing the potency and selectivity of JZL184, KML29, JW642, and JW618 against MAGL, ABHD6, and FAAH in mouse brain
proteomes. See Figure S1 for full gel profiles of each inhibitor. See also Table 1 for IC50 values calculated from gel-based ABPP experiments. Note that MAGL
migrates as two bands in the mouse brain likely due to alternative spliced isoforms (Karlsson et al., 2001).
(C) Full competitive ABPP gel showing KML29 activity against mouse brain serine hydrolase activities, which revealed selective inhibition of MAGL at
concentrations up to 1 mM and ABHD6 inhibition as the only off target at inhibitor concentrations up to 50 mM.
(D) Blockade of MAGL and FAAH by KML29 in mouse brain proteomes as measured by hydrolysis of 2-AG and AEA, respectively. Data are presented as
mean ± SEM of three independent experiments.
Gels are representative images from three independent experiments (n = 3).
See also Figure S1.
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mice using substrate assays (Figure 3B), which confirmed the
dose-dependent inhibition of MAGL and the lack of any effect
on FAAH.Chemistry & Biology 19,We also evaluated the duration of action of KML29 in vivo by
assessingMAGL activity at various time points following a single,
oral dose of the inhibitor (20 mg kg1) (Figure S2). As has been
reported previously for JZL184 (Long et al., 2009a), KML29579–588, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 581
Table 1. IC50 Values for JZL184 and HFIP Carbamates against Mouse, Rat, and Human Orthologs of MAGL, FAAH, and ABHD6
Inhibitor IC50 (nM)
JZL184 KML29 JW642 JW618
Mouse
MAGL 10a 15 (11–21) 7.6 (5.5–10) 123 (91–160)
FAAH 4,690a >50,000 31,000 (22,700–44,100) >50,000
ABHD6 3,270a 4,870 (4,120–5,760) 107 (41–285) 38 (29–50)
Rat
MAGL 262 (188–363) 43 (36–52) 14 (13–16) 385 (329–451)
FAAH 3,570 (2,540–5,020) >50,000 14,000 (12,300–17,000) >50,000
ABHD6 2,940 (1,441–6,010) 1,600 (1,260–2,040) 50 (32–78) 13 (8.9–18)
Human
MAGL 3.9 (1.8–8.1) 5.9 (4.0–9.9) 3.7 (2.3–5.9) 6.9 (4.4–11)
FAAH >50,000 >50,000 20,600 (13,000–32,600) >50,000
Serine hydrolase inhibition was measured by competitive ABPP where reductions in FP-Rh labeling of MAGL, ABHD6, and FAAH were quantified
following preincubation of proteomic samples with the indicated inhibitor. Brain membrane proteomes were used to measure inhibition of mouse
and rat enzymes, whereas human enzymes were evaluated from proteomes of transiently transfected HEK293T cells. IC50 values are reported as
the mean from three independent experiments. The 95% confidence intervals are listed in the parentheses.
See also Figures S1 and S3.
aPreviously determined IC50 values (Long et al., 2010).
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administration, the earliest time point tested. This inhibition
was sustained until 12–24 hr, at which times MAGL activity
began to return to control levels. Importantly, KML29maintained
complete selectivity for MAGL over FAAH for the duration of
the time course experiment. Brain lipid profiles for 2-AG, AA,
and AEA corroborated these gel profiles, revealing maximal
elevations of 2-AG and reductions of AA at 1 hr followed by
a gradual return toward basal levels over the 24 hr time course.
AEA levels, on the other hand, were unaltered throughout the
24 hr period.
In addition to showing low-level cross-reactivity with FAAH,
JZL184 also inhibits a handful of carboxylesterase (CES)
enzymes in peripheral tissues (Long et al., 2009b). To evaluate
whether KML29 also showed improved selectivity against
CESs, we performed competitive ABPP experiments in liver,
lung, and spleen proteomes. In vitro profiles confirmed the
superior selectivity of KML29, which showed much less cross-
reactivity with CESs in mouse lung proteomes compared to
JZL184 (Figure S2). We also evaluated the peripheral activity
and selectivity of JZL184 and KML29 in vivo by analyzing
whole-tissue homogenates from inhibitor-treated mice by gel-
based ABPP (Figure 3C). Consistent with our previous work,
JZL184 inhibited MAGL at low doses (1 mg kg1) but also dis-
played significant reactivity with several CESs in the liver, lung,
and spleen (Long et al., 2009b). KML29 produced near-complete
blockade of MAGL in these peripheral tissues at the lowest
dose tested (1 mg kg1), and, in contrast to JZL184, did not
show any detectable CES cross-reactivity until higher doses
(20–40 mg/kg), where the blockade of a single 70 kDa enzyme
was detected. This enzyme likely corresponds to carboxylester-
ase 1 (ES1), which is found abundantly in plasma (Krishnasamy
et al., 1998) and exhibits promiscuous reactivity with many
carbamates, including JZL184 (Long et al., 2009b; Alexander
and Cravatt, 2005; Bachovchin et al., 2010; Chang et al., 2011).582 Chemistry & Biology 19, 579–588, May 25, 2012 ª2012 ElsevierThe superior selectivity of KML29 over JZL184 was perhaps
most strikingly demonstrated in a chronic dosing study, where
the competitive ABPP results were compared for brain and
peripheral tissues from mice treated for 6 days with each inhib-
itor (40 mg kg1, p.o.). Under this dosing regime, JZL184 not
only inhibited MAGL but also FAAH in brain (Figure 4A), as has
been reported previously (Schlosburg et al., 2010) as well as
several CES enzymes in peripheral tissues (Figures 4B and S3).
In contrast, chronic dosing with KML29 selectively inhibited
MAGL without any effect on FAAH (Figure 4A) and minimal
cross-reactivity with CES enzymes (Figure 4B). The selectivity
of KML29 over JZL184 in chronic dosing experiments was
further demonstrated by measuring MAGL and FAAH substrate
levels in inhibitor-treated mice. KML29 was found to selectively
raise 2-AG, but not NAE levels, whereas JZL184 caused
increases in both 2-AG and NAEs (Figure 4C). Brain endocanna-
binoid hydrolytic activities were also measured ex vivo from
chronically treated mice revealing that KML29 selectively
blocked 2-AG, but not AEA-hydrolysis, whereas JZL184 in-
hibited both of these activities (Figure 4C).
KML29 Selectively Inhibits Rat and Human Orthologs
of MAGL
As has been reported previously (Long et al., 2009b), JZL184
exhibits equivalent potency for mouse and hMAGL, but substan-
tially lower activity against rat MAGL (Figure 5; Table 1). Although
the basis for JZL184’s reduced potency against rat MAGL
remains unknown, we wondered whether KML29 and other
HFIP carbamates might show improved activity for this enzyme.
Indeed, competitive ABPP analysis of rat brain homogenates
revealed that HFIP carbamates retain much of their potency
and selectivity for rat MAGL (and rat ABHD6, in the case of
JW618) (Figure 5A; Table 1). KML29, for instance, displayed an
IC50 value of 43 nM for inhibiting rat MAGL (Table 1), which
was within approximately 3-fold of its potency for mouseLtd All rights reserved
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Figure 2. Characterization of KML29-Mediated Inactivation of MAGL
(A) Proposed mechanism of MAGL inactivation by KML29. The catalytic serine (Ser122) of MAGL attacks the activated carbamate of KML29, releasing hexa-
fluoroisopropanol and forming a stable, carbamylated KML29-MAGL covalent adduct.
(B) Extracted ion chromatograms for +4 (m/z = 1408.2310) and +5 (m/z = 1126.7862) charge states corresponding to the KML29-modified adduct of the active site
tryptic peptide from DMSO-treated and KML29-treated recombinant, purified hMAGL.
(C) Proposed docking mode of KML29 to MAGL illustrated in views of the whole protein (left image) and the active site (right image). When the catalytic Ser122 is
positioned for nucleophilic attack at the carbonyl of KML29, His121 and Tyr194, which are predicted to interact with 2-AG’s head group (Bertrand et al., 2010),
show potentially favorable interactions with the KML29’s HFIP leaving group. RosettaLigand 3.3 (http://www.ncbi.nlm.nih.gov/pubmed/19041878) was used to
perform the docking, and the MAGL structure used for docking was 3JWE from the Protein Data Bank (Bertrand et al., 2010).
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Selective Inhibitors of Monoacylglycerol LipaseMAGL (IC50 = 15 nM), and maintained good selectivity relative to
rat FAAH (no detectable cross-reactivity) and ABHD6 (>20-fold
selectivity) (Table 1). We did not detect any additional off target
reactivity with other rat brain serine hydrolases for KML29 (Fig-
ure 5B) or for JW618 and JW642 (Figure S3).
We next tested whether KML29 could inhibit rat MAGL
in vivo. Wistar rats were treated with KML29 (1–40 mg kg1,
i.p.) or vehicle. After 4 hr, each rat was sacrificed, and their
tissues were collected for competitive ABPP and lipid analyses.
Gel-based ABPP revealed clear dose-dependent inhibition of
MAGL in rat brain without any detectable cross-reactivity
with FAAH or ABHD6 (Figure 5C). KML29 was slightly lessChemistry & Biology 19,potent in rats than mice, producing >90% inhibition of brain
MAGL at 40 mg kg1. Analysis of peripheral tissues revealed
complete MAGL inhibition at 5 mg kg1 in lung and spleen and
20 mg kg1 in liver (Figure S3). As was observed in mice, only
one off target was detected for KML29 in peripheral tissues of
rat by competitive ABPP, a 70 kDa serine hydrolase that is likely
the rat ortholog of ES1.
Analysis of brain lipids corroborated our competitive ABPP
results, revealing approximately 10-fold elevations in 2-AG
without alteration of AEA, PEA, or OEA (Figure 5D). We also
measured brain 2-AG hydrolytic activity, which was diminished
by 50% at 20 mg kg1 and 80% at 40 mg kg1 doses of579–588, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 583
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Figure 3. In Vivo Characterization of KML29 Activity in Mice
(A) Competitive ABPP gel of FP-Rh labeling of brain serine hydrolase activities frommice treated with JZL184 or KML29 at the indicated dose (1–40mg kg1, p.o.)
for 4 hr.
(B) Brain lipid profile for 2-AG, AA, AEA, PEA, OEA across the indicated dose range of KML29 (p.o.). 2-AG and AEA hydrolytic activity of brain tissue isolated from
KML29 treated mice (far right graph).
(C) Competitive ABPP gels of serine hydrolase activities in liver and lung tissues from mice treated with either JZL184 or KML29 (1–40 mg kg1, p.o.) for 4 hr.
Boxes mark various CES enzymes that show differential sensitivity to JZL184 versus KML29. Also see Figure S2 for in vitro inhibition of CESs by JZL184 and
KML29 in lung proteomes and ABPP gels from spleen proteomes isolated from mice treated with JZL184 and KML29.
Data are presented as mean ± SEM (n = 3 mice per group). *p < 0.05; **p < 0.01; ***p < 0.001 for vehicle-treated versus inhibitor-treated mice.
See also Figure S2.
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Selective Inhibitors of Monoacylglycerol LipaseKML29 (Figure 5E). Because ABHD6 and ABHD12 can also
hydrolyze 2-AG (Blankman et al., 2007), it is plausible that the
remaining 20% 2-AG hydrolytic activity in rat brain is due to
these enzymes, which were not inhibited by KML29 in vivo. Brain
AEA hydrolytic activity, on the other hand, was not affected at
any dose of KML29 (Figure 5E). Finally, brain AA levels were
found to decrease proportionally with the elevations in 2-AG
caused by KML29 treatment (Figure 5D). Together, these data
indicate that KML29 offers a selective, in vivo-active probe for
investigating MAGL function in rats, an objective that has not
been straightforward to achieve with past inhibitors.
Endocannabinoid hydrolase inhibitors have therapeutic
potential for treating a range of human disorders. Rodent
studies have revealed, however, that dual inhibitors of FAAH
and MAGL produce psychotropic effects that resemble the
activity of direct cannabinoid agonists (Long et al., 2009c). It
is therefore important that inhibitors maintain excellent selec-584 Chemistry & Biology 19, 579–588, May 25, 2012 ª2012 Elseviertivity for hMAGL compared to human FAAH (hFAAH). By
performing competitive ABPP assays with cell lysates from
HEK293T cells transiently transfected with hMAGL or hFAAH
cDNAs, we found that KML29 inhibited hMAGL with an IC50
value of 5.9 nM, while showing no detectable cross-reactivity
with hFAAH (Figure 5F). Other HFIP carbamates also showed
excellent potency for hMAGL and maintained high selectivity
over hFAAH (Figure 5F). We should further note that JZL184
itself displayed striking selectivity for hMAGL, exhibiting no
detectable cross-reactivity with FAAH up to 50 mM (Figure 5F).
Finally, we also measured the inhibition of hMAGL and hFAAH
by KML29 using substrate hydrolysis assays, which revealed
subnanomolar inhibition of 2-AG hydrolysis (IC50 = 0.14 nM)
and undiminished AEA hydrolysis up to 50 mM (Figure 5F).
The lower IC50 value calculated by substrate compared to
competitive ABPP assays may reflect titration of MAGL protein
in the latter format, which used higher concentrations of proteinLtd All rights reserved
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Figure 4. Characterization of Serine Hydrolase Activities and Endocannabinoid Metabolism in Mice Treated Chronically with KML29 and
JZL184
(A) Competitive ABPP gels of serine hydrolase activities in brain from mice chronically treated with vehicle, JZL184, or KML29 (40 mg kg1 day1, p.o., 6 days).
(B) Competitive ABPP gels of serine hydrolase activities in liver, lung, and spleen from mice chronically treated with vehicle, JZL184, or KML29. Boxes mark
various off targets that show differential sensitivity to JZL184 versus KML29.
(C) Brain lipid profiles and endocannabinoid hydrolytic activities measured from mice chronically treated with vehicle, JZL184, or KML29.
Data are presented as means ± SEM (n = 3 mice per group). *p < 0.05; **p < 0.01; ***p < 0.001 for vehicle-treated versus inhibitor-treated mice.
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teome/ml, respectively).
DISCUSSION
The development of selective, in vivo-active chemical probes is
often the catalyst for groundbreaking discoveries in mammalian
biology (Moellering and Cravatt, 2012; Edwards et al., 2011). An
historical look at endocannabinoid research bears this out when
considering the mechanistic insights that have been gained
following the development of selective receptor agonists and
antagonists, as well as inhibitors of endocannabinoid hydrolases
(Ligresti et al., 2009; Graham et al., 2009; Di Marzo, 2008, 2009;
De Petrocellis and Di Marzo, 2009; Fowler, 2008; Ahn et al.,
2008; Guindon et al., 2011). Selective FAAH inhibitors have
existed for at least a decade (Boger et al., 2000; Kathuria et al.,
2003), whereas selective MAGL inhibitors, such as JZL184
(Long et al., 2009a, 2010), have emerged only in the last few
years. Even within this short time period, MAGL inhibitors have
already played a key part in the discovery of MAGL’s role in
processes such as pain (Long et al., 2009a; Kinsey et al.,
2009), neuropsychiatric disorders (Sciolino et al., 2011; Bus-
quets-Garcia et al., 2011), cancer (Nomura et al., 2010, 2011a),
and neuroinflammation (Nomura et al., 2011b). Notwithstanding
the impact that JZL184 has had on our understanding of MAGL
function in mammalian biology, some limitations have con-
strained the utility of this agent and have encouraged us to
develop inhibitors with improved specificity. Of primary concern
was the low-level cross-reactivity that JZL184 displays for
FAAH, which becomes problematic in studies that require high
doses or chronic administration of the inhibitor (Long et al.,
2009a, 2009b; Schlosburg et al., 2010). Because simultaneousChemistry & Biology 19,inhibition of MAGL and FAAH elicits a unique subset of behaviors
distinct from those caused by inhibition of either FAAH or MAGL
alone (Long et al., 2009a), it is imperative that FAAH cross-reac-
tivity is avoided to allow for accurate assignment of MAGL-medi-
ated biological effects. JZL184 also inactivates a handful of CES
enzymes (Long et al., 2009b), which complicates the use of this
inhibitor to investigate peripheral functions of MAGL. With these
considerations in mind, we report herein a class of MAGL inhib-
itors, the HFIP carbamates, which exhibit vastly improved selec-
tivity for MAGL in both the brain and peripheral tissues.
We selectedHFIP carbamates because they possess a leaving
group with a pKa value that is comparable to that of p-nitrophe-
nol, the leaving group of JZL184. We also envisioned that the
HFIP group would serve as an activated isostere of the 2-AG
head group and, because of its increased size, might impart
additional selectivity for FAAH, which is particularly sensitive to
head group sterics (Lang et al., 1999). These hypotheses were
confirmed through the generation of KML29, an HFIP analog of
JZL184 that maintained the original inhibitor’s potency for
MAGL while showing greatly improved selectivity over FAAH
and CES enzymes. Even incorporation of the HFIP group into
a potent FAAH inhibitor like JZL195 converted this agent into
an MAGL/ABHD6 selective inhibitor JW642 that showed no
observable FAAH reactivity up to 10 mM. It should be empha-
sized that, in general, the MAGL/ABHD6 selectivity ratios were
not altered by incorporation of the HFIP group, suggesting that
ABHD6 selectivity is driven primarily by the amine portion of
the tested carbamates. Our competitive ABPP assays also did
not uncover any additional off targets for HFIP carbamates
across the serine hydrolase class (other than ES1), although
deeper profiling by mass spectrometry methods (Jessani et al.,
2005) will be required to more fully explore the proteome-wide579–588, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 585
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Figure 5. Inhibition of Rat and Human MAGL Enzymes by KML29
(A) Competitive ABPP gels comparing the potency and selectivity of JZL184, KML29, JW642, and JW618 against MAGL, ABHD6, and FAAH in rat brain pro-
teomes. See Figure S3 for full gel profiles of each inhibitor. See also Table 1 for IC50 values calculated from gel-based ABPP experiments.
(B) Full competitive ABPP gel showing KML29 activity against rat brain serine hydrolase activities, which revealed selective inhibition of MAGL at inhibitor
concentrations of 1 mM or less and inhibition of ABHD6 at concentrations >1 mM. No inhibition of FAAH was detected at any tested concentration of KML29.
(C) Competitive ABPP gel of brain serine hydrolase activities from rats treated with KML29 (1–40 mg kg1, i.p.) for 4 hr. Also see Figure S3 for gel profiles of liver,
lung, and spleen from rats treated with KML29.
(D) Brain lipid profile of 2-AG, AA, AEA, PEA, OEA from rats treated with KML29 (1–40 mg kg1, i.p.).
(E) Brain MAGL and FAAH activity from rats treated with KML29 (1–40 mg kg1, i.p.) as measured by 2-AG and AEA hydrolysis, respectively.
(F) Activity of JZL184, KML29, JW642, and JW618 against recombinant hMAGL and hFAAH by gel-based competitive ABPP (upper gel panels) and substrate
hydrolysis assay for KML29 (lower graph). See also Table 1 for IC50 values calculated from gel-based ABPP experiments.
Data are presented as mean ± SEM (n = 3 rats per group). *p < 0.05; **p < 0.01; ***p < 0.001 for vehicle-treated versus inhibitor-treated rats.
See also Figure S3.
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nate HFIP carbamates as a useful scaffold for inhibiting the 2-AG
hydrolases MAGL and ABHD6.
We found that KML29 selectively inactivated MAGL in vivo
without any detectable FAAH inhibition across the entire tested
dose range. This selectivity was reflected not only in measure-
ments of enzyme activity but also in brain lipid profiles, where
KML29 produced 10-fold elevations in 2-AG (and reductions
in AA) without alteration in FAAH substrates, AEA, OEA, or
PEA. KML29 proved active in both mouse and rat, thus offering
a more versatile chemical probe than JZL184 for exploring
a range of rodent behavioral models. The superior selectivity of
KML29 relative to JZL184 was also confirmed in vivo using
both acute and chronic dosing regimes (Figures 3 and 4). Finally,
we found that HFIP carbamates also display excellent potency
and specificity for hMAGL, suggesting that they could offer
a useful starting point for the development of therapeutic agents.
On this note, we were gratified to identify doses where KML29
produced partial inhibition of brain MAGL (as reflected in both
enzyme activity and brain lipid measurements; see Figures 3586 Chemistry & Biology 19, 579–588, May 25, 2012 ª2012 Elsevierand 5) because complete blockade of this enzyme is known to
produce tolerance and desensitization of CB1 receptors in
mice (Schlosburg et al., 2010).
SIGNIFICANCE
Monoacylglycerol lipase (MAGL), through catalyzing the
hydrolysis of 2-arachidonoyl glycerol to arachidonic acid,
serves as a key metabolic hub connecting the endocannabi-
noid and eicosanoid signaling networks. Small-molecule
inhibitors that selectively target MAGL are critical tools for
unraveling the functions and crosstalk between these two
lipid transmitters systems, and hold potential for treating
a wide spectrum of disorders, including anxiety, pain,
inflammation, and cancer. We report herein a class of
MAGL inhibitors, O-hexafluoroisopropyl (HFIP) carbamates,
that displays excellent potency and in vivo activity and, in
comparison to previously described O-aryl carbamates,
greatly enhanced selectivity over fatty acid amide hydrolase
and other serine hydrolases. That HFIP carbamates appearLtd All rights reserved
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ABHD6) at least in part due to the bioisosteric nature of their
leaving group leads us to speculate that this type of
substrate-mimetic strategy for covalent inhibitor design
could be generalized to develop useful probes for many
additional serine hydrolases.
EXPERIMENTAL PROCEDURES
Materials
All commercially available chemicals were obtained from Sigma-Aldrich,
Acros, Fisher, Fluka, or Maybridge and were used without further purification,
except where noted. FP-rhodamine (Patricelli et al., 2001) and JZL184 (Long
et al., 2009a) were prepared according the previously reported methods.
Detailed synthetic procedures and experimental data for KML29, JW642,
and JW618 are provided in the Supplemental Information. LC/MS lipid stan-
dards were purchased from Cayman Chemical.
In Vitro Competitive Activity-Based Protein Profiling
Proteomes (brain membrane fraction or cell lysates) (50 ml, 1.0 mg/ml total
protein concentration) were preincubated with varying concentrations of
inhibitors at 37C. After 30 min, FP-Rh (1.0 ml, 50 mM in DMSO) was added,
and the mixture was incubated for another 30 min at room temperature.
Reactions were quenched with 43 SDS loading buffer (17 ml) and run on
SDS-PAGE. Following gel imaging, serine hydrolase activity was determined
by measuring fluorescent intensity of gel bands corresponding to MAGL,
ABHD6, and FAAH using ImageJ 1.43u software.
In Vivo Administration of KML29
For intraperitoneal injections, KML29 was prepared as an emulsion in
saline:emulphor:ethanol by first adding a 1:1 mixture of ethanol:emulphor and
sonicating for 1 h with gentle heating (50C) and subsequently diluting this
cloudy mixture with saline to a final saline:emulphor:ethanol ratio of 18:1:1.
For oral administration, KML29 was dissolved in PEG300 (Fluka) by sonicating
for 1 h with gentle heating. KML29 was administered to either C57Bl/6J mice
or Wistar rats in a vehicle of either saline:emulphor:ethanol (18:1:1) for intra-
peritoneal injections or PEG300 for administration by oral gavage. After the indi-
cated dosing regimens, the animals were anesthetized using isoflurane or CO2
and sacrificed by decapitation and tissueswere immediately frozen in liquidN2.
Eachorganwaswashedwithcoldphosphate-buffered salineat 0C (332ml) to
remove excess blood and immediately dounce homogenized in PBS (1 ml).
Dounced tissue was sonicated and centrifuged (3000 rpm, 3 min, 4C) to re-
move cellular debris. Brain homogenateswere further centrifugedat high speed
(100,000g, 45 min, 4C) to separate membrane and soluble cell components.
The supernatant was removed and the remaining pellet was gently washed
with cold PBS (2 3 500 ml) and sonicated in PBS (500 ml) to resuspend. Total
protein concentrations of tissue proteomes were determined using the Bio-
Rad DC Protein Assay kit. Proteomic mixtures were either diluted to 1.0 mg/
ml total protein concentration with PBS for immediate use or aliquoted and
stored at 80C. The studies were performed with the approval of the Institu-
tional Animal Care and Use Committee at The Scripps Research Institute in
accordance with the Guide for the Care and Use of Laboratory Animals.
Recombinant Expression of Human MAGL in HEK293T Cells
hMAGL and hFAAH were expressed in HEK293T cells according to previously
reported methods (Blankman et al., 2007). Cell lysates were diluted with mock
proteomes for use in competitive ABPP experiments.
Measurement of Brain Lipids
Brain lipid levels were determined according to previously reported methods
(Long et al., 2009c).
Enzyme Activity Assays
MAGL and FAAH substrate hydrolysis measurements were determined ac-
cording to the previously reported LC-MS-based assay (Long et al., 2009a,
2009c).Chemistry & Biology 19,Expression and Purification of Recombinant Human MAGL
hMAGL was expressed in BL21(DE3) cells (Invitrogen) and purified according
to previously reported methods (Long et al., 2009b).
Detection of KML29-MAGL Adduct from KML29-Treated
Preparations of hMAGL
Tryptic digests of KML29 or DMSO-treated recombinant hMAGL were
analyzed using an LTQ-Orbitrap mass spectrometer (ThermoFisher) coupled
to an Agilent 1100 series HPLC. Labeling, sample preparation, and LC-MS/
MS analysis were performed in accordance with previously reported methods
(Long et al., 2009b).
Docking Method
The ligand structure of KML29 was generated using Chem3D (http://www.
cambridgesoft.com), and the protein structure was taken from the crystal
structure of MAGL with covalent inhibitor SAR629 (PDB code: 3JWE). Roset-
taLigand 3.3 (Davis and Baker, 2009) was used to perform the docking study.
The starting docking pose was created by aligning KML29 to the position of
SAR629 in the 3JWE structure and local docking perturbation with translation
and rotation magnitude of 3.0 A˚ and 30 was performed in all-atom mode to
generate11,500models. A distance constraint (<3.5 A˚) between the hydroxyl
oxygen of Ser132 and the carbonyl carbon of KML29 was implemented to filter
out any unsatisfying models that do not sterically support the nucleophilic
attack to the catalytic serine to the substrate ester. Final models were visually
inspected and analyzed. Figures were illustrated using PyMOL (http://www.
pymol.org).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, Supplemental Experimental
Procedures, and synthetic procedures and full characterization for com-
pounds KML29, JW642, and JW618 and can be found with this article online
at doi:10.1016/j.chembiol.2012.03.009.
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